Substitute Disclosure Fo1m
`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CFR § l.98(b))
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I Group Att Unit
`Filiug Date
`May 5, 2017
`
`Sheet _1_ of -1.Q_
`I Applicatiou No.
`15/588,461
`
`Examiner Desig.
`Initial
`ID
`1.
`
`Document
`Number
`4,814,567
`
`U.S. Patent Documents
`Publication
`Date
`03/28/1987
`
`Patentee
`Cabilly et al.
`
`Class Subclass
`
`Filing Date
`If Appropriate
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`10.
`
`11.
`
`12.
`
`13.
`
`5,116,964
`
`05/26/1992
`
`Capon et al.
`
`5,500,362
`
`03/19/1996
`
`Robinson el al.
`
`5,545,806
`
`08/13/1996
`
`Langberg et al.
`
`5,545,807
`
`08/13/1996
`
`Surani et al.
`
`5,569,825
`
`10/29/1996
`
`Langberg et al.
`
`5,625, 126
`
`04/29/1997
`
`Langberg el al.
`
`5,633,425
`
`05/27/1997
`
`Langberg et al.
`
`5,661,016
`
`08/26/1997
`
`Langberg el al.
`
`5,750,373
`
`05/12/1998
`
`Garrard et al.
`
`5,821 ,337
`
`10/13/1998
`
`Carter cl al.
`
`5,851,556
`
`12/22/1998
`
`Breton e t al.
`
`5,932,215
`
`08/03/1999
`
`De Lacharriere et al.
`
`5,938,586
`
`08/10/1999
`
`De Lacharriere et al.
`
`6,168,809
`
`08/10/1999
`
`De Lacharriere et al.
`
`6,180,370
`
`01/30/2001
`
`Queen et al.
`
`6,313,097
`
`11/06/2001
`
`Eberlein et al.
`
`6,344,438
`
`02/05/2002
`
`De Lacharriere et al.
`
`6,509,014
`
`01/21/2003
`
`De Lacharriere et al.
`
`6,521,609
`
`02/18/2003
`
`Doods et al.
`
`6,586,458
`
`07/01/2003
`
`Plachetka
`
`6,737,056
`
`05/18/2004
`
`6,767,056
`
`05/18/2004
`
`Presta
`
`Presta
`
`7,479,488
`
`01/20/2009
`
`Mueller el al.
`
`8,007,794
`
`08/20/201 l
`
`Zeller et al.
`
`8,293,239
`
`L0/23/2012
`
`Poulsen et al.
`
`14.
`
`15.
`
`16.
`
`17.
`
`18.
`
`19.
`
`20.
`
`21.
`
`22.
`
`23.
`
`24.
`
`25.
`
`26.
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
`next communication to applicant.
`
`Substitute Disclosure Form
`
`

`

`Substitute Disclosure Fo1m
`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CFR § l.98(b))
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I Group Att Unit
`Filiug Date
`May 5, 2017
`
`Sheet_2_of-1.Q_
`I Applicatiou No.
`15/588,461
`
`Examiner Desig.
`Initial
`ID
`27.
`
`Document
`Number
`8,298,536
`
`U.S. Patent Documents
`Publication
`Date
`10/30/2012
`
`Patentee
`Poulsen et al.
`
`Class Subclass
`
`Filing Date
`If Appropriate
`
`28.
`
`29.
`
`30.
`
`31.
`
`32.
`
`33.
`
`34.
`
`35.
`
`36.
`
`37.
`
`38.
`
`8,586,045
`
`11/19/2013
`
`Zeller et al.
`
`8,597,649
`
`12/03/2013
`
`Ze]le r el al.
`
`8,623,366
`
`0l/07/2014
`
`Pios et al.
`
`8,734,802
`
`05/27/2014
`
`Zeller el al.
`
`9,115,194
`
`08/25/2015
`
`Zeller et al.
`
`9,266,951
`
`02/23/2016
`
`Zelle r el al.
`
`9,328,168
`
`05/03/2016
`
`Zeller et al.
`
`9,340,614
`
`05/17/2016
`
`Zeller et al.
`
`9,346,881
`
`05/24/2016
`
`Zelle r el al.
`
`9,365,648
`
`06/14/2016
`
`Zeller et al.
`
`09/18/2012
`
`Poulsen el al.
`
`09/20/2012
`
`Poulsen et al.
`
`13/621,981
`
`13/623,206
`
`39.
`
`40.
`
`4 1.
`
`42.
`
`43.
`
`44.
`
`45.
`
`46.
`
`47.
`
`48.
`
`49.
`
`50.
`
`51.
`
`52.
`
`03/25/2013
`
`Zeller et al.
`
`05/10/2013
`
`Poulsen et al.
`
`05/10/2013
`
`Zeller el al.
`
`10/18/2013
`
`Pios et al.
`
`06/04/2014
`
`Pios el al.
`
`02/02/2015
`
`Poulsen et al.
`
`02/02/2015
`
`Zeller et al.
`
`03/20/2015
`
`Bi gal et al.
`
`05/13/2015
`
`Bigal et al.
`
`03/25/2016
`
`Poulsen et al.
`
`05/05/2016
`
`Zeller et al.
`
`2002/0162125
`
`10/31/2002
`
`Salmon el al.
`
`2003/0194404
`
`10/16/2003
`
`Greenfeder et al.
`
`13/835.394
`
`13/892, 121
`
`13/892,130
`
`14/057,747
`
`14/295,583
`
`14/612,110
`
`14/612,117
`
`14/664,715
`
`14/711,705
`
`15/081,681
`
`15/147,265
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
`next communication to applicant.
`
`Substitute Disclosure Form
`
`

`

`Substitute Disclosure Fo1m
`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CF R § l.98(b))
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I Group Att Unit
`Filiug Date
`May 5, 2017
`
`Sheet _3_ of -1.Q_
`I Applicatiou No.
`15/588,461
`
`Examiner Desig.
`Initial
`ID
`53.
`
`Document
`Number
`2004/0)10170
`
`U.S. Patent Documents
`Publication
`Date
`06/10/2004
`
`Patentee
`Pisegna et al.
`
`Class Subclass
`
`Filing Date
`If Appropriate
`
`54.
`
`55.
`
`56.
`
`57.
`
`58.
`
`59.
`
`60.
`
`61.
`
`62.
`
`63.
`
`64.
`
`2005/0234054
`
`10/20/2005
`
`Mue ller et al.
`
`2006/0183700
`
`08/1 7/2006
`
`Yater et al.
`
`2009/0220489
`
`09/03/2009
`
`Zeller et al.
`
`2010/0172895
`
`07/08/2010
`
`Boone et al .
`
`2011/0054150
`
`03/03/2011
`
`Poulsen et al.
`
`2011/025737 1
`
`10/20/2011
`
`Poulsen et al.
`
`2011/030571 l
`
`10/20/2011
`
`Poulsen et al.
`
`2012/0009192
`
`01/12/2012
`
`Zeller et al.
`
`2012/022507 5
`
`09/06/2012
`
`P ios et al.
`
`2012/0294797
`
`11/22/2012
`
`Kovacevich et al.
`
`2012/0294802
`
`11/22/2012
`
`Russo el al.
`
`2013/0216535
`
`08/22/2013
`
`Zeller et al.
`
`65.
`
`66.
`
`67.
`
`68.
`
`69.
`
`70.
`
`71.
`
`72.
`
`73.
`
`74.
`
`75.
`
`76.
`
`77.
`
`78.
`
`201 3/0295087
`
`l l/07/2013
`
`Poulsen et al.
`
`2013/0295088
`
`11/07/2013
`
`Poulsen et al.
`
`2014/0147438
`
`05/29/2014
`
`Zeller el al.
`
`2014/0308290
`
`10/13/2014
`
`Pios et al.
`
`2014/03 14767
`
`10/23/2014
`
`Pios et al.
`
`2015/0050267
`
`02/19/2015
`
`Zeller et al.
`
`2015/0266948
`
`09/24/2015
`
`Bigal et al.
`
`2015/0302690
`
`10/29/2015
`
`Poulsen el al.
`
`2015/0307607
`
`11/12/2015
`
`Bigal et al.
`
`2015/03221.42
`
`12/17/2015
`
`Zeller et al.
`
`2015/0361171
`
`12/17/2015
`
`Zeller et al.
`
`2015/0361172
`
`12/1 7/2015
`
`Zeller et al.
`
`2015/0361173
`
`12/17/2015
`
`Zeller et al.
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
`next communication to applicant.
`
`Substitute Disclosure Form
`
`

`

`Substitute Disclosure Fo1m
`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CFR § l.98(b))
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I Group Att Unit
`Filiug Date
`May 5, 2017
`
`Sheet....1__of-1.Q_
`I Applicatiou No.
`15/588,461
`
`Examiner Desig.
`Initial
`ID
`79.
`
`Document
`Number
`2016/0)68244
`
`U.S. Patent Documents
`Publication
`Date
`02/16/2016
`
`Patentee
`Zeller et al.
`
`80.
`
`60/753,044
`
`12/22/2005
`
`Benschop et al.
`
`Class Subclass
`
`Filing Date
`If Appropriate
`
`Foreign Patent Documents or Published Foreign Patent Applications
`Translation
`Examiner Desig.
`Publicatio
`Country or
`n Date
`Patent Office
`Yes
`No
`Initial
`ID
`81.
`05/15/2001 CN
`
`Document Number
`CN 1308676
`
`Class Subclass
`
`CN 1671711
`
`09/21/2005 CN
`
`EP 0 212 432
`
`03/04/1987 EP
`
`EP 1031350
`
`EP 1556020
`
`EP 1770091
`
`EP 2380592
`
`JP 07-196700
`
`JP 08-268874
`
`08/30/2000 EP
`
`07/27/2005 EP
`
`04/04/2007 EP
`
`10/26/2011 EP
`
`08/01/1995
`
`10/15/1996
`
`JP
`
`JP
`
`JP
`
`JP
`
`90.
`
`JP 2007523870
`
`08/23/2007
`
`JP 2009515942
`
`04/16/2009
`
`82.
`
`83.
`
`84.
`
`85.
`
`86.
`
`87.
`
`88.
`
`89.
`
`91.
`
`92.
`
`93.
`
`94.
`
`95.
`
`96.
`
`97.
`
`98.
`
`99.
`
`RU 2329062
`
`07/20/2008 RU
`
`WO 1991/000737
`
`01/24/1991 WIPO
`
`WO 1994/021665 Al 09/29/1994 WIPO
`
`WO 1995/05468 Al
`
`02/23/1995 WIPO
`
`WO 1996/004928 Al 02/22/1996 WIPO
`
`WO 1996/33735 Al
`
`10/31/1996 WIPO
`
`WO 1997/009046 Al
`
`03/13/1997 WIPO
`
`WO 1997/041223 Al
`
`11/06/1997 WIPO
`
`100. WO 1998/003534 Al
`
`01/29/1998 WIPO
`
`10 1. WO 1998/008630
`
`03/05/1998 WIPO
`
`102. WO 1998/009630 Al 03/1 2/1998 WIPO
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
`next communication to applicant.
`
`Substitute Disclosure Form
`
`

`

`Substitute Disclosure Fo1m
`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CFR § l.98(b))
`
`Sheet _s_ of -1.Q_
`I Applicatiou No.
`15/588,461
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I Group Att Unit
`Filiug Date
`May 5, 2017
`
`Foreign Patent Documents or Published Foreign Patent Applications
`Translation
`Examiner Desig.
`Publicatio
`Country or
`Document Number
`Initial
`ID
`n Date
`Patent Office
`Yes
`No
`103. WO 1998/011128 Al
`03/19/1998 WIPO
`
`Class Subclass
`
`104. WO 1998/056779 Al
`
`12/17/1998 WIPO
`
`105. WO 1999/058572 A 1
`
`1 l/18/1999 WIPO
`
`106. WO 2000/018764 Al 04/06/2000 WIPO
`
`107. WO 2003/093472 A2
`
`I 1/13/2003 WIPO
`
`108. WO 2003/104236 Al
`
`12/18/2003 WIPO
`
`109. WO 2004/003019 A2
`
`01/08/2004 WIPO
`
`110. WO 2004/014351 A2
`
`02/19/2004 WTPO
`
`11 1. WO 2004/050683 A2
`
`06/17/2004 WIPO
`
`112. WO 2004/082602 A2
`
`09/30/2004 WIPO
`
`113. WO 2004/082605 A2
`
`09/30/2004 WIPO
`
`11 4. WO 2004/082678 A I
`
`09/30/2004 WIPO
`
`ll5. WO 2004/083187 Al 09/30/2004 WIPO
`
`116. WO 2004/087649 A2
`
`10/14/2004 WIPO
`
`117. WO 2004/091514 A2
`
`10/28/2004 WIPO
`
`ll8. WO 2004/092166 A2
`
`10/28/2004 WIPO
`
`119. WO 2004/092168 Al
`
`10/28/2004 WIPO
`
`120. WO 2005/009962 Al 02/03/2005 WJPO
`
`12 1. WO 2005/100360 Al
`
`10/27/2005 WIPO
`
`122. WO 2006/077212 Al 07/27/2006 WIPO
`
`123. WO 2007 076336 A1
`
`07/05/2007 WIPO
`
`124. WO 2007/025212 A2
`
`03/01/2007 WIPO
`
`125. WO 2007/025286 A2
`
`03/01/2007 WIPO
`
`126. WO 2007/035906 A2
`
`03/29/2007 WIPO
`
`127. WO 2007/048026 A2
`
`04/26/2007 WIPO
`
`128. WO 2007/054809 A2
`
`05/18/2007 WIPO
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
`next communication to applicant.
`
`Substitute Disclosure Form
`
`

`

`Substitute Disclosure Fo1m
`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CFR § l.98(b))
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I Group Att Unit
`Filiug Date
`May 5, 2017
`
`Sheet_§_ of -1.Q_
`I Applicatiou No.
`15/588,461
`
`Foreign Patent Documents or Published Foreign Patent Applications
`Translation
`Examiner Desig.
`Publicatio
`Country or
`Document Number
`Initial
`ID
`n Date
`Patent Office
`Yes
`No
`129. WO 2007/061676 A2
`05/31/2007 WIPO
`
`Class Subclass
`
`130. WO 2007/076336 Al
`
`07/05/2007 WIPO
`
`131. WO2008/011190 Al
`
`01/24/2008 WIPO
`
`132. WO 2009/109908 Al 09/11/2009 WIPO
`
`133. WO 2009/109911 Al
`
`09/11/2009 WIPO
`
`134. WO 2010/006168 A2
`
`01/14/2010 WIPO
`
`135. WO 2010/075238
`
`07/01/2010 WIPO
`
`136. WO2011/024113 Al
`
`03/03/2011 WTPO
`
`Other Documents (include Author, Title, Date, and Place of Publication)
`Examiner Desig.
`Initial
`ID
`
`137.
`
`138.
`
`139.
`
`140.
`
`14 1.
`
`142.
`
`143.
`
`144.
`
`145.
`
`146.
`
`147.
`
`Document
`Abstracts of lhe XII Congress of the International Headache Society, IHC 2005, October 9-12, 2005,
`Cephalalgia 25:923, October 9-12, 2005
`Adam et al., "Severity of mucosa! inflammation as a predictor for alterations of visceral sensory
`function in a rat model," Pain 123(1-2):179-86, July 2006
`Adwanikar ct al., "Spinal CGRPl receptors contribute to supraspinaJly organized pain behavior and
`pain-related sensitization of amygdala neurons," Pain 132(1-2):53-66, November 2007
`Ahn and Goadsby, "Animal Models of Headache," The Headaches 213-219 2006, 2013
`Aiyar et al .. "Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide l receptor
`antagonist," J Pharmacolog Exp Therao 296(3):768-775, 2001
`Al-Lazikaui et al., "Standard confomiations for the canonical stmctures of inmumoglobulins," J Mol
`B iol 273(4):927-948, November 7, 1997
`Almagro and Strohl, "Antibody engineering: humanization, affinity maturation, and selection
`technique," Therapeutic Monoclonal Antibodies Chapter 13, pp31 l-334, 2009
`Aniara et al., "Expression in brain of a messenger RNA encoding a novel neuropeptide homologous
`to calcitonin gene-related peptide," Science 229(4718):1094-1097, September 13, 1985
`Ambalavanar et al., "Deep tissue inflammation upregulates neuropeptides and evokes nociceptive
`behaviors which are modulated by a neu.ropeptide antagonist," Pain 120(1-2):53-68, January 2006
`American Academy of Neurology, "New Drugs Offer Hope for Migraine Prevention," April 22,
`2014
`American Headache Society, "Initial Results for L Y295 l 742, A New Investigational Medicine for
`M igraine Prevention," 2014. Available at
`http://www.americanheadachesociety.org/initial_results _for_ Iy295 l 742 _a_ new _investigational_ me
`dicine for migraine prevention. Accessed 05/15/2014
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
`next communication to applicant.
`
`Substitute Disclosure Form
`
`

`

`Substitute Disclosure Fo1m
`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CFR § l.98(b))
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I Group Att Unit
`Filiug Date
`May 5, 2017
`
`Sheeti_of-1.Q_
`I Applicatiou No.
`15/588,461
`
`Other Documents (include Author, Title, Date, and Place of Publication)
`Examiner Desig.
`Initial
`ID
`
`148.
`
`149.
`
`150.
`
`151.
`
`152.
`
`153.
`
`154.
`
`155.
`
`156.
`
`157,
`
`158.
`
`159.
`
`160.
`
`161.
`
`162.
`
`163.
`
`164.
`
`165.
`
`166.
`
`167.
`
`168.
`
`Examiner Signature
`
`Document
`An, "Therapeutic Monoclonal Antibodies From Bench to Clinic," Wiley Chapter 31, pp. 711-762,
`2009
`Andrew et al., "Monoclonal antibodies distinguishing alpha and beta forms of calcitonin gene-
`related peptide," J Immunol Methods 134(1):87-94, November 6, 1990
`Armour et al., "Recombinant human IgG molecules lacking Fey receptor I binding and monocyte
`triirn.ering activities," Eur J lmrnunol 29(8):2613-2624, August 1999
`Arulmani et al., "Calcitonin gene-related peptide and its role in migraine pathophysiology," Eur J
`Pharmacol 500(1-3):315-330, October 1, 2004
`Arulmozlri et al., "Migraine: current concepts and emerging therapies," Vascul Phannacol
`43(3):176-187, September2005
`Asahina et al., "Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide:
`Relevance to functional effects," Proceed Nat Acad Sci USA 92(18):8323-8327, 1995
`Ashina et al., "Calcitonin gene-related peptide levels during nitric oxide-induced headache in
`patients with chronic tension-type headache," Eur J Neurol 8(2): 173-178, March 200 l
`Ashina et al., "Evidence for increased plasma levels of calcitonin gene-related peptide in migraine
`outside of attacks," Pain 86(1-2):133-1 38, May 2000
`Ashina et al., "Plasma levels of calcitonin gene-related peptide in chronic tension-type headache,"
`Neurolo~,y 55(9): 1335-1340, November 2000
`ATCC website search for PTA-6866 deposit, January 22, 2010, I page
`
`A TCC website search for PT A-6867 deposit, January 22, 20 l 0, 1 page
`
`Aziz, "Visceral hypersensitivity: fact or fiction," Gastroenterology 131(2):661-664, August 2006
`Balint and Larrick. "Antibody engineering by parsimonious mutagenesis," Gene 137(1):109-118,
`December 1993
`Bard et al., "Peripherally administered antibodies against amyloid beta-peptide enter the central
`ne,vous system and reduce pathology in a mouse model of Alzheimer disease," Nat Med 6(8):916-
`9 19, Au!!ust 2000
`Bell, "Calcitonin Gene-Related Peptide Receptor Antagonists: New Therapeutic Agents for
`Migraine," J Med Chem 57(19):7838-7858, June 24, 2014
`Bennett et al., "Alleviation of mechanical and them1al allodynia by CGRP(8-37) in a rodent model
`of chronic central pain," Pain 86(1-2):163-175, May 2000
`Benschop et al., "Development of a novel antibody to calcito1ri11 gene-related peptide for the
`treatment of osteoarthritis-related pain," Osteoarthritis Cartilage 22(4):578-585, April 2014
`Bigal et al., "Calcitonin gene-related peptide (CGRP) and migraine current understanding and state
`of development," Headache 53(8): 1230-1244, September 2013
`B igal et al., "Cardiovascular and hemodynamic parameters in women following prolonged CGRP
`inhibition using LBR-101, a monoclonal antibody against CGRP," Cephalalgia 34(12):968-976,
`October 2014
`B igal et al., "Emerging dnigs for lnigraine prophylaxis and treatment," MedGenMed 8(2): 3 1, 2006
`B i gal e t al., "Migraine in the Tripi.an Era: Progresses achieved, lessons learned and future
`developments," Arauivos de Neuro-Psiquiatria 67(2-B):559-569, 2009
`Date Considered
`
`EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
`next communication to applicant.
`
`Substitute Disclosure Form
`
`

`

`Substitute Disclosure Fo1m
`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CFR § l.98(b))
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I Group Att Unit
`Filiug Date
`May 5, 2017
`
`Sheet _JL of -1.Q_
`I Applicatiou No.
`15/588,461
`
`Other Documents (include Author, Title, Date, and Place of Publication)
`Examiner Desig.
`Initial
`ID
`
`169.
`
`170.
`
`171.
`
`172.
`
`173.
`
`174.
`
`175.
`
`176.
`
`177.
`
`178.
`
`179.
`
`180.
`
`181.
`
`182.
`
`183 .
`
`184.
`
`185.
`
`186.
`
`187.
`
`Document
`Bigal et al., "New Migraine preventive options: an update with pathophysiological considerations,"
`Rev Hosp Clin Fae Med Sao Paulo 57(6):293-298, November - December 2002
`Bigal et al., "Safety and tolerability ofLBR-101 , a humanized monoclonal antibody that blocks the
`b inding of CGRP to its receptor: Results of the Phase I program," Cephalalgia 34(7):483-492,
`December 23, 2013
`B ird et al., "Single-chain antigen-binding proteins," Science 242(4877):423-426, October 21, 1988
`Boemer et al., "Production of antigen-specific human monoclonal antibodies from in vitro-primed
`human splenocvtes," J lmmunol 147(1):86-95, July 1, 1991
`Botox Package Insett 2010, 25 pages
`Bowen et al., "Tumor necrosis factor-alpha stimulation of calcitonin gene-related peptide expression
`and secretion from rat trigeminal gangUon neurons," J Neurochcm 96(1):65-77, January 2006
`Brain and Edvinsson, "Calcitonin Gene-Related Peptide and Other Peptides," The Headaches, Third
`Edition, pages 159-164, 2006
`Brain and Grant, "Vascular actions of calciton.in gene-related peptide and adrenomedullin," Physiol
`Rev 84(3):903-934, July 2004
`Brain, "Calc itonin gene-related peptide (CGRP) antagonists: blockers of neuronal transmission in
`migraine," Brit J Pha.rmacol 142(7):1053-1054, August 2004
`Brandes et al., "Topiramate for Migraine Prevention," J Am Med Assoc 291(8):965-973, February
`25, 2004
`Brorson et al., "Mutational analysis of avidity and fine specificity of anti-levan antibodies," J
`Immuno l 163(12):6694-6701, December 15. 1999
`Brummell et al., "Probing the combining site of an anti-carbohydrate antibody by saturation-
`mutagenesis: role o f the heavy-chain CDR3 residues," B iochemistry, 32(4):1180-1 187, February 2,
`1993
`Buckley et al., "The partial inhibition of inflammatory responses induced by capsaicin using the Fab
`fragment of a selective calcitonin gene-related peptide a.ntisernm in rabbit skin," Neuroscience
`48(4):963-968, June 1992
`Buntinx et al., "Development of anti-migraine therapeutics using the capsaicin-induced dennal blood
`flow model," Brit J ClinPharmacol 80(5):992-1000, October 6, 2015
`Bmks et al., "ln vitro scanning saturation mutagenesis of an antibody b inding pocket," Proc Natl
`Acad Sci USA 94(2):412-417, January 21, 1997
`Burstein and Jakubowski, "Analgesic Triptan Action in an Animal Model of Intracranial Pain: A
`Race against the Development of Central Sensitization," Ann Neurol 55(1):27-36, January 2004
`Burstein et a.I., "Defeating Migraine Paine with Triptans: A Race against the Development of
`Cutaneous Allodynia," Ann Neurol 55(1):19-26, January 2004
`Capel et al., "Heterogeneity of human IgG Fe receptors." Imrnunomethods 4(1):25-34, February
`1994
`Caraceni et al., "Pain measurement tools and methods in clinical research in palliative care:
`recommendations of an Expert Woik.ing Group of the European Association of Palliative Ca.re," J
`Pain Symptom Manage 23(3):239-255, March 2002
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
`next communication to applicant.
`
`Substitute Disclosure Form
`
`

`

`Substitute Disclosure Fo1m
`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CFR § l.98(b))
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I Group Att Unit
`Filiug Date
`May 5, 2017
`
`Sheet....2_of-1.Q_
`I Applicatiou No.
`15/588,461
`
`Other Documents (include Author, Title, Date, and Place of Publication)
`Examiner Desig.
`Initial
`ID
`
`Document
`Carter, "Potent antibody therapeutics by design," Nature Reviews Immunology 6(5):343-57, May
`2006
`Cassel et al., "A peptide mimetic of an anti-CD4 monoclonal a ntibody by rational design," Biochem
`Bioohys Res Commun 307(1):198-205, July 18, 2003
`Cervero et al., "Visceral pain," Lancet 353(9170):2145-2148, June 19, 1999
`Chen et al, "Generation and analysis of random point mutations in an antibody CDR2 sequence:
`many mutated antibodies lose their ability to bind antigen," J Exp Med 176(3):855-866, September
`1992
`Chen et al., "Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an
`affinity-matured Fabin complex with antigen," J Mol Biol 293(4):865-881, November 5, 1999
`Chothia et al., "Conformations of immunoglobulin hypervariable regions," Nature 342(6252):877-
`883, December 21-28, 1989
`Clynes et al., "Fe receptors are required in passive and active immunity to melanoma," Proc Natl
`Acad Sci USA 95(2):652-656, January 20, 1998
`Cole et al., "The EBV-hybridoma technique and its application to human lung cancer," Monoclonal
`Antibodies and Cancer Theraov 27:77-96, 1985
`Colman, "Effects of amino acid sequence changes on antibody-antigen interactions," Res Immunol
`145(1):33-36, January 1994
`Conner et al., "Interaction of ca.lcitonin-gene-related peptide with its receptors," Biochem Soc Trans
`30(4):45 1-455, August2002
`Correia, "Stability oflgG isotypes in serum," mAbs 2(3):221-232, May/June 2010
`Covell et al., "Phannacokinetics of monoclonal immunoglobulin G 1, F(ab')2, and Fab' in mice,"
`Cancer Res 46(8):3969-3978, August 1986
`Davies and Riechmann, "Affinity improvement of single antibody VH domains: residues in all three
`hyperva.riable regions affect antigen binding," Immunotechnolot!v 2(3): 169-179, September 1996
`Davletov et al., "Beyond BOTOX: advantages and lilnitations of individual botulin.um neurotoxins,"
`Trends Neurosci 28(8):446-452, August 2005
`De Haas et al., "Fe gamma receptors of phagocytes," J Lab Clin Med 126(4):330-341, October 1995
`De Pascalis et al., "Grafting of "abbreviated" complementarity-detem1ining regions containing
`specificity-de tennini.ng residues essential for ligand contact to engineer a less immunogenic
`humanized monoclonal antibody," J Immunol 169(6):3076-3084, September 15, 2002
`Declaration Dr. Jes Olesen Nttmber 2, dated February 7, 2016, 15 pages
`
`188.
`
`189.
`
`190.
`
`19 1.
`
`192.
`
`193 .
`
`194.
`
`195.
`
`196.
`
`197.
`
`198.
`
`199.
`
`200.
`
`201.
`
`202.
`
`203.
`
`204.
`
`205.
`
`Declarntion Dr. Marcelo Biga.l and Dr. Bigal's Ci.rmculum Vitae, dated March 2, 2015, 41 pages
`
`206.
`
`Declaration of Dr. Jes Olesen regarding EP1957106, dated July 11, 2014
`
`207.
`
`208.
`
`Declaration of Dr. Leonard Presta regarding EP1957106, dated July 11, 2014
`
`Declaration of Dr. Robert Benschop regarding EP1957 106, dated July 16, 2014
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
`next communication to applicant.
`
`Substitute Disclosure Form
`
`

`

`Substitute Disclosure Fo1m
`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CFR § l.98(b))
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I Group Att Unit
`Filiug Date
`May 5, 2017
`
`Sheet_l.Q_of-1.Q_
`I Applicatiou No.
`15/588,461
`
`Other Documents (include Author, Title, Date, and Place of Publication)
`Examiner Desig.
`Initial
`ID
`
`Document
`Dela.Foy el al., "Inleractive involvement of brain derived neurotrophic faclor, nerve growth factor,
`and calcitonin gene related peptide in colonic hypersensitivity in U1e rat," Gut 55(7):940-945, July
`2006
`Denekas et a l., "Inhibilion of stimulated meningeal blood now by a calcitonin gene-related peptide
`binding mirror-image RNA oligonucleotide," Brit J Pharma.col 148(4):536-543, June 2006
`Dockray et al., "Immunoneutralization studies wilh calcitonin gene-related peptide," Ann NY Acad
`Sci 657:258-267, June 30, 1992
`Dodick el al., "Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide. for
`the prevention of frequent episodic migraine: a randomised. double-blind, placebo-contro lled,
`exploralorv phase 2 trial ," Lancet Neurol 13(11 ):1100-1107, November 2014
`Dodick el a l., "Safety and efficacy ofLY2951742, a monoclonal antibody to calcitonin gene-related
`peptide, for Ole prevention of migraine: a phase 2, randomised, double-blind, placebo-controlJed
`study." Lancet Neurol 13(9):885-892, Seplember 2014
`Dodick e t al., Authors' reply re Site of effect ofL Y2951742 for migraine prophylaxis.
`Www.thelancet.com/neueology. Vol. 14, 32-33, January 2015
`Dolgin, "Antibody drugs set to revive flagging migraine target," Nat Rev Dmg Diseov 12(4):249-
`250, April 2013
`Doods et al., "Pharmacological profile ofBIBN4096BS, the first selective small molecule CGRP
`antagonist," Brit J Phamiacol 129(3):420-423, February 2000
`Dressler et al., "Botulinum toxin: mechanisms of action," Eur Neurol 53(1):3-9, 2005
`Dufner et al., "Harnessing phage and ribosome display for antibody optimisation," Trends
`Biotechnol 24(11):523-529, November 2006
`Durham et al., "CGRP-receptor antagonisls--a fresh approach lo migraine therapy?" N Eng J Med
`350(1 1): 1073-1075, March 11, 2004
`Edvinsson and Hargreaves, "CGRP Involvement in Migraines," The HeadachesThird Edition, 289-
`299, 2006
`Edvinsson and Tfelt-Hansen, "The blood-brain barrier in migraine treatment," Cephalalgia
`28(12): 1245-1258, December 2008
`Edvinsson a nd Uddman, "Neurobiology in primary headaches," Brain Res Rev 48(3):438-456, June
`2005
`Edvinsson et al., "Effect of the CGRP receptor antagonist BIBN4096BS in huma n cerebral.,
`coronary and omenlal arteries and in SK-N-MC cells," Eur J Pharmacol 434(1 -2):49-53, January 2,
`2002
`Edvinsson et al., "Inhibitory effect ofBIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-
`Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral
`artery," Brit J Pharma.col 150(5):633-640, March 2007
`Edvinsson et al., "Inhibitory effect ofBIBN4096BS, CGRP8-37, a CGRPantibody and an RNA-
`Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral
`artery," Brit J Pharmacol 150(5):633-640, March 2007
`Edvinsson, "Blockade of CGRP receptors in the intracranial vasculature: a new target in the
`treatment of headache," Cephalalgia 24 :611-622, 2004
`
`209.
`
`210.
`
`2 11.
`
`212.
`
`213.
`
`214.
`
`215.
`
`216.
`
`217.
`
`218.
`
`219.
`
`220.
`
`221.
`
`222.
`
`223.
`
`224.
`
`225.
`
`226.
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
`next communication to applicant.
`
`Substitute Disclosure Form
`
`

`

`Substitute Disclosure Fo1m
`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CFR § l.98(b))
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I Group Att Unit
`Filiug Date
`May 5, 2017
`
`Sheet _1_1_ of -1.Q_
`I Applicatiou No.
`15/588,461
`
`Other Documents (include Author, Title, Date, and Place of Publication)
`Examiner Desig.
`Initial
`ID
`
`Document
`Edvinsson, "CGRP blockers in migraine therapy: where do they act?" Brit J Phannacol 155(7):967-
`969, December 2008
`Edvinsson, "CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine
`treatment," Brit J Clin Phannacol 80(2):193-199, August 2015
`Edvinsson, "Clinical Data on the CGRP Antagonist BIBN4096BS for Treatment ofMjgraine
`Attacks," CNS Dnig Reviews 11(1):69-76, March 2005
`Elshoutbagy et al., "Molecular cloning and characteriz.ation of the porcine calciton.in gene-related
`peptide receptor." Endocrinology 139(4):1678-1683, April 1998
`Escott and Brain, "Effect of a calciton.in gene-related peptide antagonist (CGRPs.31) on skin
`vasodilatation and oedema induced by stimulation of the rat saphenous nerve," Brit J Pharmacol
`110(2):772-776, October 1993
`Escott et al, "T1igeminal ganglion stimulation increases facial skin blood flow in the rat: a major
`role for calcitonin gene-related peptide," Brain Res 669(1):93-99, Januarv 9, 1995
`European Notice 2 October 2013 concerning the staying of proceedings due to referral to I.he EBOa
`in Gl15
`European Notice of Opposition in European Patent No. 1957106, dated July 11, 2014, 56 pages
`
`European Notice of Opposition in European Patent No. 1957106, dated July 16. 2014, 51 pages
`
`European Office Action in Application No. 10754584, dated December 16, 2013, 6 pages
`
`European Search Report in Application No. 11166787.9, dated May 8, 2012, 7 pages
`
`Evaluation of L ¥2951742 in Cluster Headache and Episodic Migraine, Clinical Trials.gov
`
`Evidence of Publication Date ofEdvinsson, CNS Drug Reviews 11(1):69-76, 2005
`
`Extended European Search Report in Application No. 16154411.9, dated July 18, 2016, 8 pages
`
`Ex1ended European Search Report in Application No. 16154418.4, dated May 10, 2016, 8 pages
`
`Extended European Search Report in Application No. 17152503.3, dated May 3, 2017, 13 pages
`Fanciullacci et al., "Increase in plasma calcitonin gene-related peptide from the extra cerebral
`circulation during nitroglycerin-induced cluster headache attack," Pain 60(2): 119-123, Febmary
`1995
`Felson et al., "The American College of Rheumatolof,•y preliminary core set of disease activity
`measures for rheumatoid a rthritis clinical trials. The Committee on Outcome Measures in
`Rheumatoid Arthritis Clinical Trials," Arthritis Rheum 36(6):729-740, June 1993
`Fischer et al., "The Nonpeptide Calcitonin Gene-Related Peptide Receptor Antagonist BIBN4096BS
`Lowers the Activity of Neurons with Meningeal Input in the Rat Spinal Trigerninal Nucleus," J
`Neurosci 25(25):5877-5883, June 22, 2005
`Forster and Dockray, "The role of calcitonin gene-related peptide in gastric mucosa! protection in
`the rat," Ex1J Physiol 76(4):623-626, July 1991
`Francis et al., "The irritable bowel severity scoring system: a simple method of monitoring irritable
`bowel syndrome and its progress," Ali ment Pham1acol Ther 11(2):395-402, April 1997
`
`227.
`
`228.
`
`229.
`
`230.
`
`231.
`
`232.
`
`233.
`
`234.
`
`235.
`
`236.
`
`237.
`
`238.
`
`239.
`
`240.
`
`241.
`
`242.
`
`243.
`
`244.
`
`245.
`
`246.
`
`247.
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
`next communication to applicant.
`
`Substitute Disclosure Form
`
`

`

`Substitute Disclosure Fo1m
`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CFR § l.98(b))
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I Group Att Unit
`Filiug Date
`May 5, 2017
`
`Sheet _ll_ of -1.Q_
`I Applicatiou No.
`15/588,461
`
`Other Documents (include Author, Title, Date, and Place of Publication)
`Examiner Desig.
`Initial
`ID
`
`248.
`
`249.
`
`250.
`
`251.
`
`252.
`
`253.
`
`254.
`
`255.